Display options
Cite
Maehira Y, Kurosaki Y, Saito T, et al. Responding to ever-changing epidemiological dynamics of Ebola virus disease. BMJ Glob Health. 2016;1(3):e000180doi: 10.1136/bmjgh-2016-000180.
Maehira, Y., Kurosaki, Y., Saito, T., Yasuda, J., Tarui, M., Malvy, D. J. M., & Takeuchi, T. (2016). Responding to ever-changing epidemiological dynamics of Ebola virus disease. BMJ global health, 1(3), e000180. https://doi.org/10.1136/bmjgh-2016-000180
Maehira, Yuki, et al. "Responding to ever-changing epidemiological dynamics of Ebola virus disease." BMJ global health vol. 1,3 (2016): e000180. doi: https://doi.org/10.1136/bmjgh-2016-000180
Maehira Y, Kurosaki Y, Saito T, Yasuda J, Tarui M, Malvy DJM, Takeuchi T. Responding to ever-changing epidemiological dynamics of Ebola virus disease. BMJ Glob Health. 2016 Nov 24;1(3):e000180. doi: 10.1136/bmjgh-2016-000180. eCollection 2016. PMID: 28588973; PMCID: PMC5321369.
Copy Download .nbib Format: NLM
Share it on

BMJ Glob Health. 2016 Nov 24;1(3):e000180. doi: 10.1136/bmjgh-2016-000180. eCollection 2016.

Responding to ever-changing epidemiological dynamics of Ebola virus disease.

BMJ global health

Yuki Maehira, Yohei Kurosaki, Tomoya Saito, Jiro Yasuda, Masayoshi Tarui, Denis J M Malvy, Tsutomu Takeuchi

Affiliations

  1. St. Luke's International University, Tokyo, Japan.
  2. Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
  3. National Institute of Public Health, Saitama, Japan.
  4. Keio University, Tokyo, Japan.
  5. Inserm 1219, University of Bordeaux & Division of Clinical Tropical Medicine, CHU de Bordeaux, Bordeaux, France.

PMID: 28588973 PMCID: PMC5321369 DOI: 10.1136/bmjgh-2016-000180

Abstract

With the incidence and mortality rates of Ebola virus disease (EVD) in Guinea, Liberia and Sierra Leone now at zero and reports of the largest and most complex EVD outbreak in history no longer on the front pages of newspapers worldwide, the urgency of that crisis seems to have subsided. During this lull after the storm and before the next one, the international community needs to engage in a 'lessons-learned' exercise with respect to our collective scientific, clinical and public health preparedness. This engagement must identify pragmatic, innovative mechanisms at multinational, national and community levels that allow research and development of next generation diagnostics and therapeutics, the safe and effective practice of medicine, and the maintenance of public health to keep pace with the rapid epidemiological dynamics of EVD and other deadly infectious diseases.

Conflict of interest statement

Competing interests: Toyama Chemicals Co., Ltd. is the developer and supplier of favipiravir for clinical studies and patient care in Guinea as well as for evacuated cases. JY and YK of Nagasaki Unive

References

  1. Lancet Infect Dis. 2015 Feb;15(2):150-1 - PubMed
  2. Lancet. 2015 Aug 29;386(9996):867-74 - PubMed
  3. Nucleic Acids Res. 2000 Jun 15;28(12):E63 - PubMed
  4. J Med Virol. 2000 Apr;60(4):463-7 - PubMed
  5. N Engl J Med. 2015 Apr 9;372(15):1381-4 - PubMed
  6. J Infect Dis. 2016 Oct 15;214(suppl 3):S203-S209 - PubMed
  7. J Clin Microbiol. 2016 Feb;54(2):359-67 - PubMed
  8. J Infect Dis. 2016 Oct 15;214(suppl 3):S243-S249 - PubMed
  9. PLoS One. 2015 Dec 21;10(12):e0145896 - PubMed
  10. Lancet. 2015 Aug 29;386(9996):857-66 - PubMed
  11. N Engl J Med. 2015 Oct 14;:null - PubMed
  12. PLoS Med. 2016 Mar 01;13(3):e1001967 - PubMed
  13. N Engl J Med. 2014 Oct 16;371(16):1545-6 - PubMed
  14. Lancet Infect Dis. 2015 Nov;15(11):1300-4 - PubMed
  15. Lancet Glob Health. 2015 Mar;3(3):e130 - PubMed
  16. Emerg Infect Dis. 2016 Feb;22(2):289-91 - PubMed
  17. N Engl J Med. 2016 Jul 21;375(3):203-4 - PubMed
  18. Antimicrob Agents Chemother. 2002 Apr;46(4):977-81 - PubMed
  19. Trends Mol Med. 2016 Feb;22(2):164-73 - PubMed
  20. Sci Data. 2015 May 26;2:150019 - PubMed
  21. J Infect Dis. 2007 Nov 15;196 Suppl 2:S199-204 - PubMed
  22. Antiviral Res. 2013 Nov;100(2):446-54 - PubMed
  23. Lancet. 2015 May 9;385(9980):1902-9 - PubMed
  24. Lancet. 2015 Feb 14;385(9968):603-4 - PubMed
  25. Euro Surveill. 2014 Dec 11;19(49):null - PubMed
  26. Euro Surveill. 2015 Mar 26;20(12):null - PubMed
  27. Infect Dis Poverty. 2014 Oct 01;3(1):35 - PubMed
  28. Nature. 2015 Dec 3;528(7580):S109-16 - PubMed
  29. J Clin Virol. 2016 Apr;77:9-14 - PubMed
  30. N Engl J Med. 2013 Jun 6;368(23):2210-8 - PubMed
  31. Am J Trop Med Hyg. 2015 Sep;93(3):438-40 - PubMed
  32. PLoS Negl Trop Dis. 2016 Feb 22;10(2):e0004472 - PubMed
  33. Lancet. 2014 Nov 22;384(9957):1833 - PubMed
  34. BMJ Open. 2016 Jan 07;6(1):e008859 - PubMed
  35. J Clin Virol. 2015 Jun;67:36-7 - PubMed
  36. Euro Surveill. 2015;20(44):null - PubMed
  37. Lancet Infect Dis. 2015 Mar;15(3):320-6 - PubMed
  38. Ther Adv Vaccines. 2015 Sep;3(5-6):125-38 - PubMed

Publication Types